Aktive Positionen von Sander van Berkel
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
SynAffix BV
 SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Technik-/Wissenschafts-/F&E-Leiter | 01.01.2010 | - |
| Gründer | 01.01.2010 | - |
Karriereverlauf von Sander van Berkel
Ausbildung von Sander van Berkel
| Radboud University Nijmegen | Graduate Degree |
Statistik
International
| Niederlande | 3 |
Operativ
| Chief Tech/Sci/R&D Officer | 1 |
| Founder | 1 |
| Graduate Degree | 1 |
Sektoral
| Health Technology | 2 |
| Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
SynAffix BV
SynAffix BV BiotechnologyHealth Technology SynAffix BV develops next-generation antibody-drug conjugates for targeted cancer and other diseases. The application of the firm?s proprietary GlycoConnect technology, comprising precision modification of a protein's native glycosylation site, allows the fast and simple construction of antibody-drug conjugates that are both stable and homogeneous. The company was founded by Floris van Delft and Sander van Berkel in 2010 and is headquartered in Oss, the Netherlands. | Health Technology |
- Börse
- Insiders
- Sander van Berkel
- Erfahrung
